NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
- Recruiting
- Jun 26, 2021
- 1 min read
Updated: May 23, 2022
PRISM High Risk Smoldering Multiple Myeloma
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma.
The names of the study drugs involved in this study are:
Daratumumab (also called Darzalex Faspro)
Bortezomib (also called Velcade)
Lenalidomide (also called Revlimid)
Dexamethasone
Sponsor:
Omar Nadeem
Collaborator:
Janssen, LP
Information provided by (Responsible Party):
Omar Nadeem, Dana-Farber Cancer Institute
Locations
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
ClinicalTrials.gov Identifier: NCT04775550
Official Title: B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma
First Posted: March 1, 2021
* Bortezomib (Velcade)
* Lenalidomide (Revlimid)
* Dexamethasone (Decadron)
* Daratumumab (Darzalex)